🇪🇺 Rhgalns in European Union

EMA authorised Rhgalns on 27 April 2014

Marketing authorisations

EMA — authorised 27 April 2014

  • Application: EMEA/H/C/002779
  • Marketing authorisation holder: BioMarin International Limited
  • Local brand name: Vimizim
  • Indication: Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
  • Status: approved

Read official source →

EMA — authorised 28 April 2014

  • Status: approved

Rhgalns in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in European Union

Frequently asked questions

Is Rhgalns approved in European Union?

Yes. EMA authorised it on 27 April 2014; EMA authorised it on 28 April 2014.

Who is the marketing authorisation holder for Rhgalns in European Union?

BioMarin International Limited holds the EU marketing authorisation.